 |
 |
Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
Winter 2007 |
EGRP BULLETIN
From the Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
The Epidemiology and Genetics Research Program (EGRP) manages a comprehensive program of grant-supported, population-based research to increase our understanding of cancer etiology and prevention. EGRP supports epidemiologic research on the determinants of cancer, including lifestyle factors (for example, tobacco, alcohol, energy balance, diet, and nutrition), medications, environmental and occupational exposures, infectious agents, personal susceptibility factors (for example, reproductive characteristics), and acquired and inherited genetic factors. Other equally important areas of investigation include clinical epidemiology, epidemiologic methods, epigenetics, and geographic information systems
Funding Opportunities
Funding Opportunities Sponsored by EGRP
EGRP is sponsoring or cosponsoring the following Program Announcements (PA/PAR) and Requests for Applications (RFA). Further information is available through the Web site of the Division of Cancer Control and Population Sciences (DCCPS) at cancercontrol.cancer.gov/funding_apply.html (under the Analytic Epidemiology Research Branch (AERB) and Clinical and Genetic Epidemiology Research Branch (CGERB), and Small Business Funding Opportunities). Or, search the NIH
Guide at grants.nih.gov/grants/guide by announcement number.
The National Institutes of Health (NIH) is transitioning to
mandatory use of the new SF424 R&R application form and electronic submission. Use of the SF424 R&R
application form and electronic submission is now mandatory for the
funding opportunities listed below. The effective dates for EGRP-sponsored
PA/PARs are given below.
Note: Meaning of grant mechanism numbers listed below:
R01桼esearch Project Grant,
R03桽mall Research Grant,
R21桬xploratory/Developmental Grant.
Epigenetic Approaches in Cancer Epidemiology
PA 07-298 for R01
PA 07-299 for R21
R01 Deadlines:
February 5, 2007 (non-AIDS),
May 1, 2007 (AIDS) |
These PAs are to stimulate population-based epidemiology research on the roles of DNA methylation markers in cancer. The objectives of the PAs are to encourage research to evaluate determinants of methylation patterns, risks of cancer associated with DNA methylation, and markers and modifiers of cancer risk using epidemiologic approaches in existing human population studies.
Contact: Mukesh Verma, Ph.D.,
Acting Chief, AERB. |
Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis
PA-07-021 for R01
PA-07-022 for R21
R01 Deadlines:
February 5, 2007 (non-AIDS),
May 1, 2007 (AIDS) |
These PAs are to encourage researchers working in the field of cancer control and prevention to (1) improve existing models for cancer risk and prognosis by developing innovative research projects that use existing data, (2) develop new models for cancer risk and prognosis, and (3) validate new models and evaluate their utility in research and clinical settings. The PAs provide a mechanism of support for investigators to address two major challenges in model development: integrating diverse types of data, and ensuring adequate validation. The PAs are not for applications that focus on the identification and characterization of prognostic/diagnostic markers. They are cosponsored with the Applied Research Program (ARP), Division of Cancer Control and Population Sciences (DCCPS), and the Division of Cancer Treatment and Diagnosis (DCTD).
Contact: Isis S. Mikhail,
M.D., M.P.H., Dr.P.H., CGERB Program
Director. |
Pilot Studies in Pancreatic Cancer
PA-06-314 for R03
PA-06-303 for R21 |
These trans-NCI PAs are to encourage innovative research across multiple disciplines for better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. Inquiries about cancer control, epidemiology, and survivorship research proposals are handled by EGRP. Please refer to the PAs for the complete list of contacts.
Contact: Mukesh Verma, Ph.D.,
Acting Chief, AERB. |
Research on Malignancies in AIDS and Acquired Immune Suppression
PA-07-173 for R01
PA-06-338 for R21
R01 Deadlines:
February 5, 2007 (non-AIDS),
May 1, 2007 (AIDS) |
These PAs are to encourage research that will improve
our understanding of the biological basis of development and progression
of cancer in the context of Human Immunodeficiency Virus (HIV)
infection and Acquired Immune Deficiency Syndrome (AIDS) or acquired
immune suppression not associated with HIV infection, such as organ
transplantation. Novel approaches to discovery and preclinical
development of novel therapeutic agents and biomarkers for early
diagnosis and monitoring of disease progression are encouraged.
Molecular epidemiologic studies of the role of chronic latent viruses
and their interaction with one another or with environmental factors
in the context of acquired immune suppression or HIV infection
leading to the development of tumors or lesions with oncogenic
potential are also of interest. These PAs are cosponsored with
the NCI抯 Division of Cancer Biology (DCB), Division of Cancer
Treatment and Diagnosis (DCTD), and Office of AIDS Malignancies
Program, and with the National Institute of Dental and Craniofacial
Research (NIDCR).
Contacts: Mukesh Verma, Ph.D.,
Acting Chief, AERB; or
Vaurice Starks, AERB
Program Director. |
Studies of Energy Balance and Cancer in Humans
PA-07-176 for R01, competitive supplements to existing NIH grants
PA-06-405 for R21
R01 Deadlines:
February 5, 2007 (non-AIDS),
May 1, 2007 (AIDS) |
These PAs invite investigator-initiated research
to define factors affecting energy balance and mechanisms influencing
cancer risk, prognosis, and quality of life. These studies may
range from new analyses of existing datasets to additional collection
of data and biological specimens in ongoing investigations. To
be eligible for these PAs, an applicant must have previously collected
measures from human subjects on two or more of the following exposures:
diet, physical activity, body composition, and/or related biomarkers
(such as blood, urine, exfoliated cells, and/or tissue samples).
The knowledge gained is anticipated to provide additional information
to better understand the relationships among energy balance, cancer
risk, and prognosis. These PAs are cosponsored with NCI抯 Office
of Cancer Survivorship (OCS), Division of Cancer Control and Population
Sciences (DCCPS), and Division of Cancer Prevention (DCP).
Contact: Virginia (Ginny)
Hartmuller, Ph.D., R.D., AERB Program
Director. |
Exfoliated Cells, Bioactive Food Components, and Cancer
PA-07-207 for R01
PA-06-360 for R03
PA-06-359 for R21
R01 Deadlines:
February 5, 2007 (non-AIDS),
May 1, 2007 (AIDS) |
These PAs are to encourage grants that focus on research to critically evaluate the use of exfoliated cells to monitor the physiological effects of dietary bioactive food components thought to be involved with cancer prevention. The objective is to encourage interdisciplinary collaborations between scientists engaged in research using exfoliated cells and those conducting nutrition research related to cancer prevention. This research will help determine the utility of exfoliated cells as a model system to monitor both the absorption and retention of bioactive food components and the concomitant alterations in genomic and epigenetic events that occur in intact cells.
Contact: Virginia (Ginny)
Hartmuller, Ph.D., R.D., AERB Program
Director. |
| Small Business Grants |
Small businesses may obtain support through the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer Research (STTR) Programs. These programs are designed to support innovative research that has the potential for commercialization. The STTR Program encourages partnerships between small businesses and research institutions. Learn more about the programs and about topics of special interest to EGRP in the areas of tools for assessment of exposures and biomarkers and tools for cancer epidemiology studies at epi.grants.cancer.gov/ResPort/sbir.html. Also, see the article at the bottom of this page.
Contact: Jay Choudhry, M.S.,
EGRP Program Director. |
Small Grants Program for Cancer Epidemiology
PAR-06-294 for R03 |
This PAR invites applications relating to cancer
epidemiology with a primary focus on etiologic
cancer research. These are short-term awards intended to provide
support for pilot projects,
testing of new techniques, or development of innovative projects
that could provide a basis for
more extended research. Note that this PAR stipulates a 10-page limit
to the research plan,
including tables and figures.
Contact: Mukesh Verma, Ph.D., Acting
Chief, AERB; e-mail: vermam@mail.nih.gov
Our
Division of Cancer Control and Population Sciences (DCCPS) also
sponsors a PAR for Small
Grants for Behavioral Research in Cancer Control (PAR-06-458).
Contact: Veronica Chollette,
R.N., M.S., Behavioral Research Program; e-mail: vc24a@nih.gov |
Update on Funding Opportunities for Small Businesses
The National Institutes of Health (NIH) and other government agencies issued a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Omnibus Solicitation to request grant applications for 2007.
This solicitation includes:
- PA-07-280, to invite small businesses to submit SBIR grant (R43/R44)
applications, and
- PA-07-281, to invite small businesses to submit STTR
grant (R41/R42) applications.
EGRP is particularly interested in supporting small business research
on the development of tools for assessing exposures and biomarkers
and tools for cancer epidemiology studies. Additional
information on potential research topics.
The 2007 deadlines for grant applications in response to these funding
announcements are April 5, August 5, and December 5. For AIDS and AIDS-Related
applications, the deadlines are May 1, September 1, and January 2,
2008. Only electronic submissions through Grants.gov will be accepted.
Along with NIH, this solicitation was also issued by the Centers for
Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration
(FDA). More about this announcement can be found in the NIH
Guide for Grants and Contracts under notice NOT-OD-07-036
, or on the NIH
Small Business Funding Opportunities Home Page.
Direct questions about this announcement to Jay
Choudhry, M.S., EGRP
Program Director.
NIH Pathway to Independence Award Offers Support for New Investigators
The NIH Pathway to Independence Award Program facilitates the transition
of promising postdoctoral scientists to research independence by providing
opportunities to receive both mentored and independent research support
from the same award. NIH expects to award between 150 and 200 grants
per year (the PA expires in 2010). The award features an initial 1�year
mentored phase that allows investigators to complete their supervised
research work, publish results, and search for an independent research
position. The second, independent phase, in years 3� provides awardees
who secure an assistant professorship or equivalent position significant
research support, including full indirect costs that will allow them
to establish their own research program and successfully apply for an
NIH investigator-initiated (R01) grant. During the full program period,
NIH will provide almost $400 million in support. All NIH Institutes and
Centers are participating. The next deadlines for new applications are
June 12 and October 12.
Additional information can be found in the NIH
Guide, PA-07-297.
President Bush Participates in Roundtable on Cancer Prevention
President Bush visited NIH on January 17 for a roundtable discussion on advances in cancer prevention. His visit coincided with the release of new statistics from the American Cancer Society (ACS).
During the meeting, Bush highlighted some of the progress made in cancer
control. He noted that there has been a drop in the number of cancer
deaths in America for the second consecutive year. According to the ACS
report Cancer Statistics, 2007, there were 3,014 fewer deaths from cancer
in 2004 compared to 2003 (the most recent statistics available).
During the roundtable discussion, NIH Director Elias Zerhouni, M.D.,
summarized the strategy of NIH, and emphasized the importance of understanding
molecular pathways, genes, and our relationship with the environment
to improve cancer prediction. 揫We want to] do the research that will allow us to predict better, to personalize, to have a precision-type approach rather than a 憃ne size fits all,� and the hope is to be preemptive,� said Zerhouni. Advances in genetics can allow a more personalized approach to health. John Niederhuber, M.D., NCI Director, highlighted NCI抯 focus on genetics by discussing two major cancer breakthroughs, the Cancer Genetic Markers of Susceptiblity (CGEMS) project and the Cancer Genome Atlas. CGEMS is an NCI initiative that looks at the entire genome to pinpoint genes or gene locations that make people susceptible to prostate, breast, and, soon, pancreatic cancer. The Cancer Genome Atlas is a collaboration between NCI and the National Human Genome Research Institute to characterize the genomic changes that occur in all types of cancer.
Bush also noted the value of genetic research. He hopes Congress will
pass legislation that makes genetic discrimination illegal, so that research
participants will not fear discrimination.
The report Cancer Statistics, 2007 is available in the January/February
2007 issue of A Cancer Journal for Clinicians. In addition,
a new ACS report that highlights cancer trends, Cancer
Facts & Figures 2007, is available. Additional information about President
Bush抯 visit to NIH is available.
Feedback on Center for Scientific Review
The Center for Scientific Review (CSR) at the National Institutes of
Health (NIH) will hold six one-day Open House Workshops in 2007 to solicit
input from leaders in the scientific community and other stakeholders
on its integrated review groups and study sections. Feedback from the
workshops will be used to help realign CSR抯 review groups and ensure
that these groups are adequately representing and evaluating current
and emerging scientific fields. CSR receives all NIH grant applications,
assigns them to the proper Institutes and Centers, and organizes the
groups and study sections that evaluate the majority of grant applications.
The CSR抯 peer review groups have not been broadly assessed by the scientific
community since a reorganization plan was developed 7 years ago. The
first workshop, on CSR抯
neuroscience study sections, is scheduled to take place on March 2. The
five remaining workshops are scheduled every other month during 2007.
These workshops will address other CSR study sections: the behavioral
and social sciences study sections, the disease-based study sections,
the integrated biological study sections (two workshops), and the biomolecular
study sections. All of the workshops will be held in the Natcher Conference
Center on the NIH campus in Bethesda, MD. Comments from the workshops
will be posted online, and stakeholders can submit additional input for
consideration. Input from these workshops and public comment will be
presented to the NIH Peer Review Advisory Committee to guide CSR as it
works to implement changes and address concerns raised.
Find additional information
and registration forms, or contact the Open
House Project Coordinator at 301-435-1114.
EGRP Staff Will Attend the AACR Annual Meeting
Look for EGRP staff at the American Association for Cancer Research
(AACR) Annual Meeting, in Los Angeles, April 14�. The following EGRP
staff are attending:
If interested, schedule a time to meet with an EGRP staff member by
sending an e-mail in advance. You may also wish to see EGRP抯 Daniela Seminara, Ph.D., M.P.H., speak as a panel member at the forum 揅ancer Consortia: Opportunities and Challenges� on Tuesday, April 17 at 8:30 a.m.�30 a.m.
EGRP Staff News
 EGRP Director of Communications Linda Anderson Retires After a 30-year
Career
Linda Anderson, M.P.A., EGRP抯 Director of Communications, retired in January 2007 after a 30-year career with the Federal Government. Linda led all communications activities, including publication of the EGRP
Bulletin and EGRP Research Highlights, e-mail distribution of EGRP
News Flash messages, and creation and display of tabletop exhibits at conferences. Prior to coming to EGRP, Linda was an information officer, writer-editor, science writer, public health advisor, and acting director and director of communications within the government.
Linda authored and co-authored numerous journal articles, newsletters,
press releases, fact sheets, background documents, reports, and other
materials on cancer-related topics. She earned an NIH Plain Language
Award for the Cancer Genetics Network recruitment brochure Finding
Ovarian Cancer Early in High-Risk Women, an NIH Group Merit Award
for the Long Island Breast Cancer Study Project, and an NIH Plain Language
Award for her contribution to the Division of Cancer Control and Population
Sciences (DCCPS)-online newsletter. She earned five awards for planning
and coordinating town meetings about breast cancer on Long Island, coordinating
a prostate cancer epidemiology workshop for researchers, serving as Project
Officer for the Geographic Information System for Breast Cancer Studies,
and for her promotional work for research initiatives.
 Britt C. Reid, D.D.S., Ph.D., has joined EGRP as a Program Director.
Previously, Dr. Reid was an Assistant Professor in the Department of
Health Promotion and Policy at the University of Maryland Dental School,
where he was director for the graduate course Applied Scientific Evidence,
an epidemiology consultant for the NIH-funded Data Resource Center, and
global data director for the Special Olympics oral health program. Dr.
Reid also was a Principal Investigator for two NIH-funded grants addressing
head and neck cancers and co-Investigator for two additional NIH-funded
grants addressing the impact of comorbid conditions on health outcomes.
He has served as a reviewer of epidemiology and cancer content for seven scientific journals and two NIH study sections, and has authored or coauthored 26 manuscripts in peer-reviewed scientific journals since the year 2000.
Prior to his academic career, Dr. Reid practiced clinical dentistry
in Washington, D.C., and as a Naval Officer in support of the Fleet Marine
Force in Japan. He received his dental degree (D.D.S.) from the University
of Michigan and Ph.D. in epidemiology from the Johns Hopkins School of
Public Health.
 Sheri Dixon Schully, Ph.D., has returned to EGRP as a Program Director.
She previously was with EGRP during a 6-month rotation as a Presidential
Management Fellow (PMF), where she worked with the Cancer Family Registries.
Dr. Schully also completed a rotation at NCI抯 Division of Cancer Epidemiology and Genetics, where she organized activities for the Cancer Genetic Markers of Susceptibility Initiative, and at NCI抯 Office of the Director, where she worked with the Small Business Innovation Research Program. During her tenure as a PMF, Dr. Schully was selected as a C-Change intern. C-Change is a national organization of cancer leaders, co-chaired by former President George H.W. Bush and First Lady Barbara Bush, who have a shared vision of collaborating to conquer cancer. Dr. Schully received her Ph.D. in biological sciences (with a concentration in population genetics) from Louisiana State University. While at the university, she also was a Teaching Assistant instructing science majors on basic biology principles and themes and a Graduate Assistant evaluating equipment and curricula for a K� science outreach program
Grantsmanship
NIH Changes Standard Receipt Dates for Grant Applications
Changes in the standard receipt dates for grant applications submitted to NIH, the Agency for Healthcare Research and Quality (AHRQ), and the National Institute for Occupational Safety and Health (NIOSH) began this January for both paper and electronic applications.
Some key points are:
- The heaviest receipt dates from all agencies on Grants.gov are the
first of the month, the 15th of the month, the first Friday, and last
day of the month. The new receipt dates have been intentionally offset
from these dates to improve Grants.gov response times for NIH applicants.
- Effort was made to use recurring days of the month for simplicity
(i.e., new R01s would come in on February 5 and renewals on March 5).
- The R01s, NIH抯 most frequently used mechanism, were kept early in
the receipt window to allow time for processing. The receipt date of
the 5th of the month was chosen to be sure the bulk of submissions
that come in on the receipt date and the few days prior miss Grants.gov抯 heaviest volume days.
Applications for Requests for Applications (RFAs) and Program Announcements
(PAs, PARs, PASs) with special receipt dates continue to be due on
the specified dates listed in the Funding Opportunity Announcements
(FOA). For an application to be considered on time, it must be received
by Grants.gov by 5 p.m. local time of the applicant institution (NIH
Guide NOT-OD-06-050). The changes are announced in the NIH
Guide, NOT-OD-07-001.
| |
Receipt Cycle I |
Receipt Cycle II |
Receipt Cycle III |
Program Project Grantsand Center Grants梐ll P Series
new, renewal,
resubmission, revision |
January 25
(old date Feb. 1) |
May 25
(old date June 1) |
September 25
(old date Oct. 1) |
Research Grants桼10, R18, R24, R25
new, renewal, resubmission, revision* |
January 25
(old date Feb. 1, March 1) |
May 25
(old date June 1, July 1) |
September 25
(old date Oct. 1, Nov. 1) |
Research-Related and OtherPrograms梐ll S and G Series,C06, M01
new,
renewal, resubmission, revision* |
January 25
(old date Feb. 1) |
May 25
(old date June 1) |
September 25
(old date Oct. 1) |
Institutional Ruth L. KirschsteinNational
Research Service Awards桾
Series (Training)**
new, renewal, resubmission, revision* |
January 25
(old date Jan. 10) |
May 25
(old date May 10) |
September 25
(old date Sept. 10) |
Research Grants桼01
new |
February 5
(old date Feb. 1) |
June 5
(old date June 1) |
October 5
(old date Oct. 1) |
Research Career Development梐ll K Series
new |
February 12
(old date Feb. 1) |
June 12
(old date June 1) |
October 12
(old date Oct. 1) |
Research Grants桼03, R21, R33,R21/R33, R34, R36
new |
February 16
(old date Feb. 1) |
June 16
(old date June 1) |
October 16
(old date Oct. 1) |
Academic Research EnhancementAward (AREA)桼15
new, renewal, resubmission,
revision* |
February 25
(no change) |
June 25
(no change) |
October 25
(no change) |
Research Grants桼01
renewal, resubmission, revision* |
March 5
(old date March 1) |
July 5
(old date July 1) |
November 5
(old date Nov. 1) |
Research Career Development梐ll K Series
renewal, resubmission,
revision* |
March 12
(Old date March 1) |
July 12
(old date July 1) |
November 12
(old date Nov. 1) |
Research Grants桼03, R21, R33,R21/R33, R34,
R36
renewal, resubmission,
revision* |
March 16
(old date March 1) |
July 16
(old date July 1) |
November 16
(Old date Nov. 1) |
New Investigator桼01
resubmission* for those applicationsinvolved
in pilot ONLY |
March 20
(no change) |
July 20
(no change) |
November 20
(no change) |
Small Business InnovationResearch (SBIR),
Small BusinessTechnology Transfer (STTR) Grants桼43, R44, R41, and R42
new, renewal, resubmission,
revision* |
April 5
(old date April 1) |
August 5
(old date Aug. 1) |
December 5
(old date Dec. 1) |
Individual Ruth L. KirschsteinNational Research
Service Awards(Standard)梐ll
F Series Fellowships
new, renewal, resubmission* |
April 8
(old date April 5) |
August 8
(old date Aug. 5) |
December 8
(old date Dec. 5) |
Conference Grants and ConferenceCooperative
Agreements桼13, U13
new,
renewal, resubmission, revision* |
April 12
(old date April 15) |
August 12
(old date Aug. 15) |
December 12
(old date Dec. 15) |
AIDS and AIDS-Related Grants
ALL of the mechanisms cited above
new,
renewal, resubmission, revision* |
May 1
(no change) |
September 1
(no change) |
January 2
(no change) |
* The new Grants.gov terminology (included in the table above) corresponds to traditional NIH terms:
- New = new
- Resubmission = a revised or amended application
- Renewal = Competing Continuation
- Continuation = Noncompeting Progress Report
- Revision = Competing Supplement
** Institutional Research Training Grants (T32) are accepted by many
NIH Institutes and Centers (IC) for only one or two of the dates. Applicants
should contact the relevant IC for specific dates.
At present, NIH receives and processes applications for NIOSH and for
components of Centers for Disease Control and Prevention (CDC) that
participate in the Omnibus Solicitation for Small Business Innovation
Research grant applications. The application deadlines above apply
only to these two groups of applications and not to other CDC submissions.
Advance Notice of 8 Weeks a MUST to Submit Large-Budget Applications!
NIH requires grant applicants with a requested budget of $500,000 or more in
direct costs in any year to contact the appropriate program staff member before
submitting applications to the NIH Center for Scientific Review (CSR) for peer
review. The Notice in the NIH Guide states that approval must be sought 6 weeks
prior to submitting the grant. However, approval for NCI epidemiology applications
must be sought at least 8 weeks prior to submission to CSR to complete the
internal processing by the deadline.
Investigators must follow this policy, speak to
the appropriate Program Director, and respond to requests
for information. If advance notice about the proposed study and budget
is not received, applications will be returned, causing a delay in
submission and review of one round. This policy applies to new, competing
continuation, competing supplement, and amended/revised applications.
The policy does not apply to applications submitted in response to
RFAs or in response to other announcements that include specific budgetary
limits. See the NIH Guide, NOT-OD-02-004 and
NOT-CA-02-029.
Multiple Principal Investigator Option Extended to Most Grant Applications
The NIH will allow research grant applicants and their institutions
to identify more than one Principal Investigator on most applications
submitted electronically through Grants.gov, including Research Project
Grants (R01), Small Research Grants (R03), and Exploratory/Development
Grants (R21). The aim of this multiple-Principal Investigator option
is to encourage multidisciplinary and other types of 搕eam science� projects
that are not optimally served by the single-Principal Investigator model.
Projects suitable for the multiple-Principal Investigator option could
include as few as two Principal Investigators who are jointly responsible
for the scientific and technical direction of the project. Further information
is available on NIH抯 Multiple
Investigators Web page and in the NIH
Guide, NOT-OD-07-017.
Direct questions to multi_PI@mail.nih.gov.
New Online Training Resources on Electronic Submissions Now Available
Three new modules have been added to the NIH Electronic Submission
of Grant Applications training Web site at era.nih.gov/ElectronicReceipt/training.htm.
These modules cover (1) finding grant opportunities in the NIH Guide
for Grants and Contracts and downloading the application package, (2)
checking the submission status and viewing the assembled application in eRA
Commons for the Signing Official, and (3) checking the submission status and
viewing the assembled application in eRA Commons for the Principal Investigator.
These modules are highlighted as new on the training Web site.
New Publications
 The article The Emergence of Networks in Human
Genome Epidemiology: Challenges and Opportunities was published in the January edition of the journal Epidemiology.
This article discusses the consortia approach to genetic and genomic epidemiology.
Co-authors include Deborah (Debbie) Winn, Ph.D., EGRP Acting Associate Director,
and Daniela Seminara, Ph.D., M.P.H., Biologist and Scientific Program Officer
for the Cancer Family Registries.
 The Nation抯 Investment in Cancer Research: A Plan and Budget
Proposal for Fiscal Year 2008. This publication describes NCI抯
strategies and plans to decrease the burden of cancer. It highlights scientific
accomplishments and opportunities, from broad analyses of research trends
to examples of targeted projects, and trends affecting current and future
research, progress on NCI objectives, a description of NCI抯 infrastructure
for implementing its objectives, and a proposed budget for Fiscal Year
2008. The annual document has been called the 揃ypass Budget� because
NCI submits its budget request directly to the President for review and
transmittal to Congress. This report
is available online. Print copies
can be ordered from NCI抯 Publications Locator.
 NCI Cancer Bulletin. New each week, NCI抯 online newsletter
provides information about Institute programs and initiatives. Regular
features include the NCI Director抯
update, information on funding opportunities, research highlights, legislative
updates, interviews with important people in cancer research, and a calendar
of meetings and presentations. Access
the Bulletin and subscribe.
 Geographic Information Systems (GIS) and Cancer
Research. This publication
provides information about how GIS can be used in cancer research, including
to gain information about environmental exposures, monitor emerging trends
for cancer control, look at health disparities, conduct research on behaviors,
and provide the basis for health policy. It describes applications for
GIS technology in various areas of cancer research, describes GIS tools
and resources, landmark GIS studies, and current funding opportunities
in GIS with NCI抯 Division of Cancer Control and Population Sciences
(DCCPS). The document is available via NCI抯
Publications Locator.
 The third edition of Cancer Epidemiology and Prevention, edited by David
Schottenfeld, M.D., and Joseph M. Fraumeni, Jr., M.D., has been published
by Oxford University Press. Many of the authors are current or former
EGRP grantees and NCI scientists. The book provides a comprehensive presentation
of the global burden and patterns of cancer occurrence, along with new
developments in our understanding of cancer causation and prevention.
Special attention is given to epidemiologic approaches that incorporate
molecular biomarkers based on genomic and other emerging technologies,
providing new insights into the role of genetic predisposition and gene-environment
interactions in cancer induction. New chapters are included on social
class disparities in cancer incidence and mortality, the role of obesity
and physical inactivity in cancer etiology, the potential effects of
electromagnetic fields and radiofrequency radiation, and principles of
cancer chemoprevention. Deborah (Debbie) Winn, Ph.D., EGRP Acting Associate
Director, is a co-author of the chapter 揅ancers of the Oral Cavity and Pharynx.� Other NCI authors are from our Division of Cancer Control and Population Sciences (DCCPS), Division of Cancer Epidemiology and Genetics (DCEG), and Division of Cancer Prevention (DCP).
Sources of Information on Grant Policies, Funding, and Training
Subscribe to EGRP Bulletins and News Flashes
You are welcome to invite
others to subscribe to receive occasional Bulletins and News
Flashes from the Epidemiology and Genetics Research Program (EGRP).
|
